医学
危险系数
内科学
比例危险模型
肾脏疾病
心肌梗塞
心力衰竭
冲程(发动机)
蛋白尿
队列
心脏病学
肾功能
置信区间
肾
机械工程
工程类
作者
Richard S. Shulman,Wei Yang,Debbie L. Cohen,Peter P. Reese,Jordana B. Cohen,Lawrence J. Appel,Jing Chen,Harold I. Feldman,Alan S. Go,James P. Lash,Robert G. Nelson,Mahboob Rahman,Panduranga S. Rao,Vallabh O. Shah,Mark Unruh
出处
期刊:Hypertension
[Ovid Technologies (Wolters Kluwer)]
日期:2024-08-01
标识
DOI:10.1161/hypertensionaha.124.23184
摘要
BACKGROUND: In contrast to proteinuric chronic kidney disease (CKD), the relative cardioprotective benefits of antihypertensive medications in nonproteinuric CKD are unknown. We examined long-term cardiovascular outcomes and mortality in patients with nonproteinuric CKD treated with renin-angiotensin system inhibitors (RASIs) versus other antihypertensive medications. METHODS: Among participants of the CRIC study (Chronic Renal Insufficiency Cohort) without proteinuria, we used intention-to-treat analyses with inverse probability of treatment weighting and Cox proportional hazards modeling to determine the association of RASIs versus other antihypertensive medications with a composite cardiovascular outcome (myocardial infarction, stroke, heart failure hospitalization, and death) and mortality. Secondary analyses included per-protocol analyses accounting for continuous adherence and time-updated analyses accounting for the proportion of time using RASIs during follow-up. RESULTS: A total of 2806 participants met the inclusion criteria. In the intention-to-treat analyses, RASIs versus other antihypertensive medications were not associated with an appreciable difference in cardiovascular events (adjusted hazard ratio [aHR], 0.94 [95% CI, 0.80–1.11]) or mortality (aHR, 1.06 [95% CI, 0.88–1.28]). In the per-protocol analyses, RASIs were associated with a lower risk of adverse cardiovascular events (aHR, 0.78 [95% CI, 0.63–0.97]) and mortality (aHR, 0.64 [95% CI, 0.48–0.85]). Similarly, in the time-updated analyses, a higher proportion of RASI use over time was associated with a lower mortality risk (aHR, 0.33 [95% CI, 0.14–0.86]). CONCLUSIONS: Among individuals with nonproteinuric CKD, after accounting for time-updated use, RASIs are associated with fewer cardiovascular events and a lower mortality risk compared with other antihypertensive medications. Patients with nonproteinuric CKD may benefit from prioritizing RASIs for hypertension management.
科研通智能强力驱动
Strongly Powered by AbleSci AI